tbuckley/cabot-search huggingface dataset:
SAT0627-HPR Educational Needs of French Rheumatology Nurses Are Not Limited To Inflammatory Arthritis Management. Results of The Multicentric “Caire” Survey:
Authors: C. Beauvais, S. Pouplin, A. Mulliez, F. Fayet, R.M. Poilverd, L. Gossec, S. Perrot, C. L'Amour, M. Mezières, M.P. Aubert, N. Jaccaz Vallée, C. Savel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> EULAR recommendations aim to promote the role of the nurse in the management of inflammatory arthritis (IA) (1). A survey among French nurses in 2014–2015 showed a gap between educational needs and reported competences of French nurses regarding IA management (2). <h3>Objectives</h3> The objective was to investigate competencies in other rheumatic and musculoskeletal conditions (RMD), patient education and research compared with those found in IA. <h3>Methods</h3> The list of potentially useful competencies for RN was validated by a multidisciplinary group (2). The survey was conducted through 3 on-line quesitionnaires in Dec 2014-Jan 2015 (2) then in Jan-May 2015, including 78, 72, 70 items. For each item, the RN were asked on a 4 point likert scale if they believed they had acquired the competency and considered it of importance. <h3>Results</h3> All RMD were adressed: rheumatoid arthritis RA, spondyloarthritis SpA, connective tissue diseases (CTD), other RMD e.g osteoarthritis, osteoporosis, low back pain. The cross-functional skills were pain management, patient-nurse communication, patient education, research. Respectively 104, 71 et 64 RN responded the 3 on-line investigations, 92% female, 70% worked full time, 70% in a university hospital; 30–29% declared qualifications in patient education, 9–20% in pain management, 6–17% in research. Reported competencies were very good in DMARDS, analgesics and NSAIDs, good in patient-nurse communication and patient education. In other fields, educational needs are high, particularly for non-pharmacological treatments, CTD, osteoarthritis, low back pain and research (table). Practical skills were less than cognitive skills. <h3>Conclusions</h3> This multicentric survey provides accurate information on French RN educational needs. They are greater in the management of RMD other than RA and SpA. These results should be considered in elaborating a curriculum to improve RN competencies. <h3>References</h3> van Eijk-Hustings Y et al. Ann Rheum Dis. 2012;71:13–9. Beauvais Ann Rheum Dis 2015;74(Suppl2):1326. <h3>Acknowledgement</h3> Members of the committee for the French Rheumatology Nurse educational course <h3>Disclosure of Interest</h3> None declared
Acidity-triggered charge-convertible nanoparticles that can cause bacterium-specific aggregation in situ to enhance photothermal ablation of focal infection
Authors: Chiranjeevi Korupalli, Chieh-Cheng Huang, Wei-Chih Lin, Wen-Yu Pan, Po-Yen Lin, Wei-Lin Wan, Meng-Ju Li, Yen Chang, Hsing-Wen Sung
Journal: Biomaterials (2016)
AB0782 Two-Year Study of Bone Metabolism in Liver Transplant Patients. Influence of Antiresorptive Treatment and Evaluations before Surgery
Authors: J. Valero Sanz, E. Grau Garcia, J. Ivorra Cortés, L. González Puig, I. Chalmeta Verdejo, C. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuan, K. Arévalo Ruales, R. Negueroles Albuixech, J. Fragio Gil, I. Martínez Cordellat, C. Alcañiz Escandell, G. Poveda Marín, C. Nájera Herranz, D. Hervás Marín, D. Moya Nájera, A. Moya Herraiz, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoporosis is a frequent complication in patients with chronic liver disease, especially in end-stage and when there is a history or evidence of chronic cholestasis. But even more important is that liver transplant patients, in the first few months after the transplant there may be an accelerated loss of bone mass, which also means greater osteopenia and osteoporosis incidence and fracture risk. <h3>Objectives</h3> To study the effect in bone metabolism of antiresorptive treatments in patients undergoing liver transplantation (LT), as well as an evaluation prior to transplant to decrease the risk of osteoporosis. <h3>Methods</h3> We collected patients undergoing LT, where data is available at transplant (month 0) and 6–12–18–24 month follow-up after surgery. We collected data of bone metabolism biomarkers, densitometric and antiosteoporotic treatment. Statistical analysis was carried out using R software 3.2.3. <h3>Results</h3> We selected 172 patients with LT, and 56 of them had completed the 24 months follow-up. Of the total cohort, 89.7% are men, with a mean age at transplantation of 57.7±6.7 years. The 89% of patients were supplemented with 25-OHVitamin-D after surgery and during follow-up, the 6.4% initiated treatment with bisphosphonates and 2.3% with denosumab. Improved vitamin D levels and normalization of the values of PTH, beta-CTX and P1NP were observed. The t-score densitometric value for the first 12 months of follow-up dropped slightly, to increase again at 24 months of follow-up. This situation is still more pronounced in lumbar spine (t-score -1.49±1.29 after surgery and -1.29±1.1 at 24 months of follow-up). Statistical analysis yield a significant influence of antiresorptive treatment (P&lt;0.0001) on the normalization densitometric values, as well as on the normalization of vitD (P=0.003), bCTX (P=0.03) and P1NP (P=0.02). In contrast, obesity correlates with altered densitometric (P=0.003). Finally, there is a clear difference in bone metabolism biomarkers between LT patients evaluated and treated before surgery and those evaluated after surgery (P&lt;0.0001). <h3>Conclusions</h3> In general, there is a normalization of serum vitamin D levels and biomarkers of bone metabolism in two years after surgery. The use of antiresorptive treatment is crucial to reach with stage, as well as to establish an evaluation before surgery and treat the patient if is required. <h3>Disclosure of Interest</h3> None declared
SAT0136 Patients with Rheumatoid Arthritis and High Levels of Anti-Cyclic Citrullinated Peptide Antibody under Treatment with High-Dose Glucocorticoid Frequently Fall: Five-Year Findings of The Tomorrow Study: Table 1.
Authors: S. Anno, K. Inui, K. Mamoto, T. Okano, Y. Sugioka, M. Tada, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk for falls. However, previous prospective studies have not included controls to clarify whether RA per se represents a risk factor for falls. <h3>Objectives</h3> The present study prospectively compares the five-year incidence of falls and risk factors influencing falls between patients with RA and controls based on the findings of the TOMORROW study (UMIN000003876) that started in 2010. <h3>Methods</h3> We compared anthropometric parameters, bone mineral density, disease activity, and the incidence of falls in 202 patients with RA (mean age, 58.6 years; medication with biological agents, 54.9%) and in 202 age- and sex-matched healthy volunteers (controls; mean age, 57.4 years) over a five-year period. We also analyzed risk factors for falls in the patients using multivariate regression analysis. <h3>Results</h3> The rate of individuals who fell did not significantly differ between patients with RA (n=101, 50%) and Controls (n=91, 45%) within the five-year period. However, the incidence of falls was significantly higher in the patients than the controls (0.39 vs. 0.21/person-years (py); <i>p</i> =0.002). Multivariate linear regression analysis adjusted for fall risk factors including age, sex, smoking, and body mass index, revealed the association of a history of falls at entry into the study and RA morbidity with the number of falls in all participants (β =0.248, 0.144, <i>p</i> &lt;0.01, respectively). In addition, anti-cyclic citrullinated peptide antibody (CCP), matrix metalloproteinase (MMP)-3 levels, a history of falls at entry, mean MMP-3 values, disease activity score 28 (DAS28-CRP), modified Health Assessment Questionnaire (mHAQ) score and glucocorticoid dosage (GC) over five years were related to the number of falls among the patients (Table 1). <h3>Conclusions</h3> The rate of individuals who fell did not significantly differ between the patients and controls, but the incidence of falls was significantly higher in the patients within the five-year period. A higher titer of anti-CCP, higher doses of GC, and a high anti-CCP level were the most significantly associated with an increased frequency of falls among patients with RA. <h3>Disclosure of Interest</h3> None declared
Molecular Response to Treatment Predicts Outcome in Isolated, but Not in Combined Bone Marrow Relapses of Childhood Acute Lymphoblastic Leukaemia: Interim Results of Trial ALL-REZ BFM 2002
Authors: Cornelia Eckert, Arend Stackelberg, Nikola Hagedorn, Andrea Barth, Karl Seeger, Guenter Henze
Journal: Blood (2008)
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.
Authors: Pierre Fenaux, G.J. Mufti, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, A.F. List, S.D. Gore, J.F. Seymour, E. Hellstrom-Lindberg, J.M. Bennett, J.C. Byrd, J.T. Backstrom, L.S. Zimmerman, D.R. McKenzie, C.L. Beach, L.R. Silverman
Journal: Blood (2007)
FRI0063 Predictors of Flare in A Cohort of RA in Remission after 12 Months of Follow-Up
Authors: A. Cuervo, J. Ramírez, V. Ruíz-Esquide, R. Celis, M.V. Hernández, J. Inciarte-Mundo, R. Sanmartí, J.D. Cañete
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Definitive biomarkers have not been identified to predict flares in patients with RA in clinical remission. <h3>Objectives</h3> To determine clinical, serological and ultrasonografic variables predicting disease relapse at 12 months of follow-up in a cohort of RA patients in clinical remission. <h3>Methods</h3> We included consecutively RA patients in clinical remission defined as DAS28-ESR &lt;2.6 for &gt;6months evaluated by two independent rheumatologist from our Arthritis Clinic. Complete clinical and biological assessment, determination of serum levels of angiogenic and proinflamatory cytokines, and ultrasound scans of both hands were performed at baseline and after 12 months of follow-up. Risk factors odds ratio (OR) related with 12 months flare were adjusted with multivariate logistic models. <h3>Results</h3> Sixty patients with RA in remission were included; 78.3% were female. Median age was 53 years (range: 31–74), weight was 67 kg (47–108). Disease and remission mean duration were 111.9 ± 86.4 and 37 months, respectively. 71% of patients were RF positive and 81% were ACPA positive. Patients taking low-dose prednisone, csDMARDs and bDMARDs were 16 (26%), 47 (78%) and 28 (46.7%), respectively. At baseline, 66% had power-doppler (PD) signal and 48% also had synovial hyperplasia grade ≥2, so fulfilling the criteria previously defined of ultrasound defined active sinovitis (UdAS). Twenty-six (43%) patients had disease flare during the follow-up. In the univariate analysis, disease flares were more frequent in patients with PD signal (p=0.056) or UdAS (p=0.117), and significantly less frequent in patients with mild-moderate intake of alcohol. However, in the multivariate analysis, only higher ESR levels (OR: 1.1, 95%CI: 1–1.1), higher weight (OR: 3.1, 95%CI: 1.4–7) and low-dose prednisone treatment (OR: 1.8, 95%CI: 1.2–2.8) were independent risk factors at baseline for disease flares. This model has a sensitivity of 76.9% (95%CI: 56.4–91), a specificity of 76.5% (95%CI: 58.8–89.3), a predictive positive value of 71.40% (95%CI: 52.4–88.4), a predictive negative value of 81.3% (95%CI: 62.7–91.7) and a good predictive power (ROC: 0.849, IC 95%: 74.4–95.4%). We did not find differences between angiogenic or proinflammatory cytokine serum levels and not differences in RAMRIS between patients relapsing or maintaining the remission at baseline. <h3>Conclusions</h3> This prospective study suggests that higher ESR levels, higher weight and low-dose prednisone treatment are relevant independent risk factors for development of disease flares in patients with RA in clinical remission. However, imaging data (Ultrasound or MRI) or angiogenic/cytokine serum levels were no predictors of flare in this study. <h3>Disclosure of Interest</h3> None declared
High-Resolution Genome-Wide Profiling of DNA Copy Number Abnormalities and Gene Resequencing in Pediatric Acute Myeloid Leukemia (AML).
Authors: Ina Radtke, Charles G. Mullighan, Masami Ishii, Jing Ma, Xiaoping Su, Salil Goorha, Ramapriya Ganti, Zhongling Cai, Letha A. Phillips, Stanley B. Pounds, James Dalton, Susana C. Raimondi, Jeffrey E. Rubnitz, Raul C. Ribeiro, Sheila A. Shurtleff, James R. Downing
Journal: Blood (2007)
PTU-114 Treatment Switching Patterns between Gaviscon Formulations and Other Alginates Prescribed for Gastroesophageal Reflux Disease (GERD) In Routine, General Practice
Authors: D Williams, CJ Currie, P Okhuoya, J Wilkinson, E Berni
Journal: Gut (2016)

<h3>Introduction</h3> GERD is a common and bothersome ailment that can lead to more severe gastrointestinal disease. Treatment discontinuation is a metric that provides an insight into treatment satisfaction and treatment efficacy. Various alginate products are available to alleviate the symptoms of GERD, and Gaviscon formulations represent the most commonly used product. The purpose of this study was to characterise the epidemiology and treatment switching patterns between Gaviscon formulations and other alginate products indicated for GERD. <h3>Methods</h3> Data for this study were derived from a 10% sample of the UK population in the Clinical Practice Research Datalink (CPRD). Eligible subjects had a first diagnosis of GERD in 2009, allowing for 5 year follow-up period. Survival analysis methods were used to analyse switching patterns within alginate groups comparing alginate versus Gaviscon. Potential clinical indicators of people likely to switch were identified using a classification and regression tree (CART), and significant covariates then used as co-variables for a Cox regression model. <h3>Results</h3> Following exclusions, 22,625 patients were identified for analysis. The average age at time of diagnosis of these patients was 52 years, with 57.1% females. 69.6% of patients were current alcohol drinkers compared to the three other alcohol groups, never drunk (14.9%), previous drinkers (3.1%) and missing (12.5%). The Kaplan-Meier plot (figure) illustrates that the time to a first switch within alginates was quicker for patients that experience a switch from a generic alginate to Gaviscon compared to Gaviscon to a generic alginate. The proportion of patients that had not switched at the end of treatment years were as follows: year 1: 0.97 vs 0.91, year 2: 0.94 vs 0.85, year 3: 0.92 vs 0.82, year 4:0.91 vs 0.77 and year 5:0.88 vs 0.75. CART modelling elucidated three co-variables associated with switching treatment: first prescription of generic alginate or Gaviscon, gender, and alcohol status. In the Cox model there was a corresponding difference in these metrics: alginate to Gaviscon versus Gaviscon to alginate (aHR = 1.77, 95% CI 1.38–2.28). <h3>Conclusion</h3> There was an association between the type of alginate prescribed for GERD treatment and the likelihood of switching. Patients were more likely to switch from alginate to Gaviscon compared with the reverse. The data showed that those patients taking Gaviscon from first prescription were less likely to switch to an alternative alginate treatment. Possible explanations for this include potential differences in efficacy, or differences in organoleptic properties. <h3>Disclosure of Interest</h3> D. Williams Conflict with: This work was funded by Reckitt Benckiser, C. Currie: None Declared, P. Okhuoya: None Declared, J. Wilkinson: None Declared, E. Berni: None Declared
AB0205 Il-22 Serum Levels as A Biomarker for Erosive Disease in Rheumatoid Arthritis
Authors: J. Leipe, H. Schulze-Koops, A. Skapenko
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Consistent with models of experimental arthritis implicating IL-22 in the development of joint destruction we could previously demonstrate that elevated IL-22 serum levels were associated with the development of erosive disease in patients with early RA. <h3>Objectives</h3> To study value of IL-22 as a marker for erosive disease in established RA, to assess whether IL-22 is increased in other joint destructive rheumatic diseases, and to evaluate the influence of comorbidities on IL-22 serum levels. <h3>Methods</h3> We measured serum IL-22 levels by Enzyme-Linked Immunosorbant Assay (ELISA) and analyzed their correlation to erosive disease (assessed by radiographs of hand and feet) and clinical parameters in patients with established RA (n=142), psoriatic arthritis (n=15), gout (n=15), age-matched patients with hypertension (n=10), diabetes (n=10), coronary heart disease (n=10), and healthy individuals as controls. <h3>Results</h3> 81 of 142 patients with established RA demonstrated elevated IL-22 levels compared with the range of healthy controls. A significant greater percentage of these “IL-22 high” patients (59%) demonstrated erosive disease compared the “IL-22 normal” patients (37%, p&lt;0.05). In the “IL-22 high” compared to “IL-22 normal” group the fractions of patients positive for RF (70% vs 83%) and ACPA (74% vs 64%) were slightly higher, however not statistically significant different. Similar, measures of disease activity including DAS28 (2.3 vs 2.8) and CRP (0.5 vs 0.3 mg/dl) only tended to be higher in the “IL-22 high” than the “IL-22 low” group. Irrespective of erosive joint disease, patients with psoriatic arthritis and gout demonstrated lower IL-22 levels compared to established RA and only slightly higher than healthy individuals. Patients with hypertension, diabetes and coronary heart disease had IL-22 serum levels comparable to healthy controls. <h3>Conclusions</h3> High IL-22 levels are associated with erosive disease also in established RA, potentially in parts independent of serology, and might serve as a marker for joint destruction also in this cohort. <h3>Disclosure of Interest</h3> None declared
Severe abdominal pain in an 85 year old woman
Authors: Joseph Dalby Sinnott, David C Howlett
Journal: BMJ (2016)

An 85 year old woman was admitted to hospital with a rigid, mildly distended, severely painful abdomen and absent bowel sounds. She was in atrial fibrillation and was hypotensive. A computed tomography (CT) scan was performed. What does it show (fig 1⇓)?



Fig 1 

The CT scan shows widespread peripheral branching gas within the liver. This is consistent with a diagnosis of portal venous gas, and in this case was secondary to small bowel ischaemia.

### Discussion

The non-contrast CT scan (fig 2⇓) shows widespread branching gas that is …
High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement
Authors: Saulius Girnius, David C Seldin, Karen Quillen, Nancy T Andrea, John Mark Sloan, John L Berk, Frederick L Ruberg, Hans Meier-Ewert, Vaishali Sanchorawala
Journal: Blood (2011)
Next-Generation Deep Sequencing Reveals Multiple Ighv Clones in One Third of CLL Patients Defining New Prognostic Subgroups and Improving Previous Classification
Authors: Basile Stamatopoulos, Adele Timbs, Hélène Dreau, Ruth Clifford, Pauline Robbe, Adam Burns, Joanne Mason, Anna Schuh
Journal: Blood (2015)
Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment
Authors: Qu Cui, Masahiro Abe, Hirokazu Miki, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Ayako Nakano, Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto
Journal: Blood (2010)
Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation
Authors: Natasha A Jain, Eleftheria K. Koklanaris, Kamna Chawla, Priyanka A Pophali, Jeffrey K. Klotz, Christopher S. Hourigan, Bipin N. Savani, Sawa Ito, A. John Barrett, Minoo Battiwalla
Journal: Blood (2012)
CEBPA Single Nucleotide Polymorphism (SNP) rs34529039 As An Independent Adverse Prognostic Factor in Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Mahmoud Aljurf, Hala Abalkhail, Tarek Owaidah, Fahed Almhareb, Naeem A. Chaudhri, Claudia Ulrike Walter, Mohammed Toulimat, Hazzaa Al Zahrani, Said Mohamed, Walid Rasheed, Fahad Alsharif, Maher Albitar
Journal: Blood (2011)
Abstract 15655: Thrombin Induces Expression Of Sphingosine Kinase-1 (SPHK-1) In Human Vascular Smooth Muscle Cells Via The mRNA Stabilising Protein HuR. Inhibition By Dabigatran Reduces Vascular SPHK-1 Expression And Atherosclerotic Burden In Vivo
Authors: Swen Ermler, Andreas Bohm, Anke C Rosenkranz, Karsten Schror, Bernhard H Rauch
Journal: Circulation (2011)

Objective: Sphingosine-1-phosphate (S1P) is a cellular signaling lipid generated by sphingosine kinase-1 (SPHK-1). This study investigated the potential regulation of SPHK-1 in thrombin-stimulated ...
Rabbit Anti-Thymocyte Globulin (rATG) Administrated Concomitantly with Liver Delivery of AAV2-hFIX Can Promote Inhibitor Formation In Rhesus Macaques.
Authors: Jonathan D. Finn, Patricia Favaro, J. Fraser Wright, Federico Mingozzi, Katherine A. High, Valder R. Arruda
Journal: Blood (2010)